1/254
Looks like no tags are added yet.
acetaminophen (OTC) brand name, drug class, MOA
-Tylenol
-Analgesic
-Acetaminophen is a centrally acting analgesic and antipyretic with minimal anti-inflammatory properties. Its analgesic mechanism is unknown but may be through central inhibition of prostaglandin synthesis.
acetaminophen (OTC) indications
-pain, headache, fever
acetaminophen (OTC) BW
Risk of medication errors (injection only) and hepatotoxicity
acetaminophen (OTC) CI
Hypersensitivity to acetaminophen, active acute hepatic dysfunction; do not use with other acetaminophen-containing products
acetaminophen (OTC) AE
none known
acetaminophen (OTC) DDI
1. Busulfan (Acetaminophen decreases glutathione levels in the blood and tissues, and busulfan is eliminated from the body via conjugation with glutathione)
2. Isoniazid, phenytoin, zidovudine, alcohol (Additive hepatotoxicity with acetaminophen)
3. Warfarin (Acetaminophen may interfere with clotting factors or interfere with warfarin metabolism with an increased risk of bleeding)
acetaminophen (OTC) pt counseling
1. Do not exceed the maximum recommended daily dose; higher doses may result in hepatic injury, including severe hepatotoxicity and death.
2. Avoid alcohol (< 3 drinks/d), especially if use is chronic.
3. Use the provided measuring device with individual products to reduce dosing errors.
4. The infant and children's formulation is the same strength (160 mg/5 mL).
allopurinol brand name, drug class, MOA
-Zyloprim
-Xanthine Oxidase Inhibitor; Antigout
-Allopurinol decreases the production of uric acid by inhibiting the action of xanthine oxidase, the enzyme that converts hypoxanthine to xanthine and xanthine to uric acid.
allopurinol indications
-Gout, mild
-Gout, moderate to severe
-Hyperuricemia, tumor lysis syndrome prophylaxis
-Nephrolithiasis prophylaxis due to calcium stones
allopurinol CI
Hypersensitivity to allopurinol
allopurinol AE
None known
allopurinol DDI
1. Didanosine (Increased didanosine bioavailability)
2. Azathioprine (Xanthine oxidase needed to eliminate azathioprine metabolite, mercaptopurine; when xanthine oxidase is inhibited by allopurinol, increases azathioprine effect and toxicity)
3. Cyclophosphamide (Increased cyclophosphamide concentration)
4. Fluorouracil (Decreased fluorouracil efficacy)
5. Warfarin (Increased INR)
allopurinol pt counseling
1. Take after meals to lessen gastric irritation.
2. Maintain adequate hydration during therapy to prevent kidney stones.
3. Patient should avoid alcohol and caffeine while taking allopurinol.
4. Seek medical attention if signs and symptoms of myelosuppression, agranulocytosis (severe neutropenia), or Stevens-Johnson syndrome (flulike symptoms, spreading red rash, or skin/mucous membrane blistering) occur.
baclofen brand name, drug class, MOA
-Lioresal, Ozobax, Fleqsuvy
-Centrally Acting Skeletal Muscle Relaxanr
-Baclofen inhibits both monosynaptic and polysynaptic reflexes at the spinal level, possibly by hyperpolarization of afferent terminals, although actions at supraspinal sites may also occur and contribute to its clinical effect. Baclofen is an analogue of γ-aminobutyric acid (GABA), but there is no conclusive evidence that actions on GABA systems are involved in the production of its clinical effects.
baclofen indications
-Spasticity
baclofen BW
Avoid abrupt discontinuation of intrathecal product
baclofen CI
Hypersensitivity
baclofen AE
Nausea, asthenia, dizziness, somnolence, confusion
baclofen DDI
none known
baclofen pt counseling
1. Because of the possibility of sedation, patients should be cautioned regarding the operation of motor vehicles or dangerous machinery while taking baclofen.
2. Patients should be cautioned that the CNS effects of baclofen may be additive to those of alcohol and other CNS depressants.
3. Oral packet doses should be taken within 2 h when mixed with food.
buprenorphine/naloxone brand name, drug class, MOA
-Suboxone, Zubsolv
-Opioid Partial Agonist and Antagonist Combination. C-III
-Buprenorphine is a μ-opioid receptor partial agonist and a -opioid receptor antagonist. Naloxone is a μ-opioid receptor antagonist that causes opioid withdrawal when injected parenterally and is included in the formulation to reduce the risk of abuse.
buprenorphine/naloxone indications
-opioid use disorder
buprenorphine/naloxone CI
Hypersensitivity
buprenorphine/naloxone AE
Vasodilation, sweating, headaches, insomnia, constipation, GI distress, opioid withdrawal, dizziness
buprenorphine/naloxone DDI
1. Barbiturates, benzodiazepines, centrally acting muscle relaxants, opioids, phenothiazines (Additive CNS depression)
2. Opioid agonists/antagonists, opioid antagonists (Precipitation of withdrawal symptoms)
3. CYP3A4/5 inducers (Increased buprenorphine metabolism reduces buprenorphine effectiveness)
4. CYP3A4/5 inhibitors (Decreased buprenorphine metabolism increases risk of buprenorphine toxicity)/
buprenorphine/naloxone pt counseling
1. Use a stool softener and/or laxative to prevent constipation.
2. May cause drowsiness; avoid driving or other tasks requiring motor coordination.
3. Avoid alcohol and other CNS depressants.
4. Do not crush or swallow the sublingual tablet.
5. Place the tablet under the tongue until it is dissolved.
6. If you take ≥2 tablets at a time, place all of the tablets under the tongue together.
7. If this is uncomfortable, place 2 tablets at a time under the tongue and repeat the process until all tablets have been taken.
8. If you are using the sublingual film, place the film under the tongue until it is dissolved.
9. If you need to take an additional film, place the new film on the opposite side from the first film.
10. Do not chew, swallow, or move the film after placing it under the tongue.
11. After the tablet/film has dissolved, swish and swallow water.
12. Do not brush teeth until 1 h after tablet/film administration.
capsaicin (OTC) brand name, drug class, MOA
-Capsaicin-P, Zostrix
-Topical Analgesic
-Capsaicin is an agonist of the transient receptor potential vanilloid 1 (TRPV1) receptor, found in nociceptive nerve fibers. Activation of TRPV1 by capsaicin results in depolarization, initiation of action potential, and pain signal transmission to the spinal cord, and subsequent desensitization and inhibition of pain transmission initiation.
capsaicin (OTC) indications
-minor pain
capsaicin (OTC) CI
Hypersensitivity to capsaicin or chili peppers
capsaicin (OTC) AE
Local erythema and pain
capsaicin (OTC) DDI
none known
capsaicin (OTC) pt counseling
1. For skin application, wash and dry area.
2. Apply thin layer or patch to affected area.
3. You may wear gloves when putting on.
4. Do not apply to open wounds or damaged skin, and treated area should not be exposed to heat or direct sunlight.
5. Avoid contact with eyes or other mucous membranes.
6. Do not bandage.
7. Do not bathe, shower, or swim within 1 h of applying topical product.
8. Remove patch 1 h before bathing, showering, or swimming; patches should not be used >5 d consecutively.
9. Local skin irritation declines with continuous use, while treatment effect continues; intermittent use may delay decline in local irritation.
10. If medication comes in contact with hands, wash hands well after application and carefully avoid touching eyes, mouth, nose, or groin area.
carisoprodol brand name, drug class, MOA
-Soma, Vanadom
-Centrally Acting Skeletal Muscle Relaxant. C-IV
-Carisoprodol blocks interneuronal activity in descending reticular formation and spinal cord, resulting in muscle relaxation.
carisoprodol indications
-Disorder of musculoskeletal system
carisoprodol CI
Hypersensitivity to carisoprodol or meprobamate, acute intermittent porphyria
carisoprodol AE
Drowsiness
carisoprodol DDI
1. CYP2C19 inducers (Increased carisoprodol metabolism reduces carisoprodol effectiveness)
2. CYP2C19 inhibitors (Decreased carisoprodol metabolism increases risk of carisoprodol toxicity)
3. CNS depressants (opioids, benzodiazepines, alcohol) (Additive sedative effects)
carisoprodol pt counseling
1. Patients should avoid drinking alcohol.
2. Patients should avoid activities requiring mental alertness or coordination until drug effects are known, as drug may cause dizziness or sedative effects.
3. Patients withdrawing from prolonged therapy should be monitored carefully for withdrawal symptoms, including seizures.
celecoxib brand name, drug class, MOA
-Celebrex, Elyxyb
-Cyclooxygenase-2 inhibitor
-Inhibition of the COX-2 enzyme isoform is thought to be responsible for the anti-inflammatory effects of NSAIDs.
celecoxib indications
-osteoarthritis
-rheumatoid arthritis
-Ankylosing spondylitis
-Acute pain, primary dysmenorrhea
-Migraine, acute treatment
celecoxib BW
Cardiotoxicity, contraindicated perioperatively for CABG, serious gastrointestinal disorders
celecoxib CI
Asthma, urticaria, or allergic-type reaction following aspirin or other NSAID administration; CABG surgery, treatment of perioperative pain, hypersensitivity to sulfonamides
celecoxib AE
Diarrhea, HTN, headaches, GI distress
celecoxib DDI
1. Aspirin, SSRIs (Additive GI toxicity)
2. Aliskiren, ACEIs, ARBs, thiazide diuretics (Decreased diuretic and antihypertensive efficacy via decreased renal prostaglandin production)
3. CYP2C9 inducers (Increased celecoxib metabolism reduces celecoxib effectiveness)
4. CYP2C9 inhibitors (Decreased celecoxib metabolism increases risk of celecoxib toxicity)
5. CYP2D6 and 2C8 substrates (Decreased metabolism and increased toxicity of substrates)
6. Lithium (Increased lithium levels, unknown mechanism)
7. Pemetrexed (Decreased renal clearance and increased toxicity of pemetrexed)
8. Warfarin (Both substrates for CYP2C9, competitive metabolism)
celecoxib pt counseling
1. May take with food or milk to decrease GI upset.
2. May open capsule and pour into a teaspoon of applesauce.
codeine brand name, drug class, MOA
-Tylenol with Codeine
-Opioid. C-II when in combination with acetaminophen, C-III for tablets, C-V for liquid
-Codeine is 3-methylmorphine, a phenanthrene opioid with very low affinity for opioid receptors. Its analgesic activity appears to result from conversion to morphine.
codeine indications
-pain
codeine BW
Abuse, REMs, respiratory depression, accidental ingestion, CYP2D6 in children, neonatal withdrawal syndrome, interactions with CYP3A4/5, 2D6, avoid concomitant benzodiazepines and CNS depressants, risk of medication errors with oral solution /
codeine CI
Hypersensitivity to codeine or morphine, use in patients
codeine AE
Nausea, vomiting, constipation, somnolence
codeine DDI
1. Alcohol, opioids, and other CNS depressants (Additive CNS and respiratory depression)
2. Buprenorphine, opioid agonists/antagonists, opioid antagonists (Precipitation of withdrawal symptoms)
4. CYP2D6 inhibitors (Decreased effectiveness of codeine; prevents conversion of codeine to active metabolite, morphine)
5. SSRIs, SNRIs, TCAs, MAOIs, triptans (Increased risk of serotonin syndrome)
codeine pt counseling
1. Take with food to decrease stomach upset and nausea.
2. Avoid grapefruit or grapefruit juice due to risk of increased codeine toxicity.
3. If using chronically, use laxative for preventing constipation.
4. May cause drowsiness; avoid driving or other tasks requiring motor coordination.
5. If using an acetaminophen-containing product, advise patients to avoid other acetaminophen-containing products for pain.
6. Avoid alcohol.
colchicine brand name, drug class, MOA
-Colcrys, Gloperba, Mitigare, Lodoco
-Antigout
-Exact mechanism unknown. In patients with gout, may interrupt the cycle of monosodium urate crystal deposition in joint tissues and the resultant inflammatory response that initiates and sustains an acute attack. Colchicine also inhibits urate crystal deposition, which is enhanced by a low pH in the tissues, probably by inhibiting oxidation of glucose and subsequent lactic acid production in leukocytes.
colchicine indications
-Gout, acute
-Familial Mediterranean fever
-Reduction in MI, cardiovascular death, stroke, and coronary revascularization risk
colchicine CI
Hypersensitivity to colchicine; concurrent use with strong CYP3A4/5 inhibitors in patients with renal or hepatic failure, myelodysplasia
colchicine AE
Diarrhea, nausea
colchicine DDI
1. CYP3A4/5, P-glycoprotein inducers (Increased colchicine metabolism or transport reduces colchicine effectiveness)
2. CYP3A4/5, P-glycoprotein inhibitors (Decreased colchicine metabolism or transport increases risk of colchicine toxicity)
3. Lipid-lowering agents (fibrates, statins) (Coadministration of colchicine and lipid-lowering agents may result in myopathy and rhabdomyolysis; mechanism unknown)
colchicine pt counseling
1. Instruct patient on appropriate dosing strategy for gout flares (dosing to symptom relief or onset of adverse effects, particularly diarrhea).
2. Grapefruit and grapefruit juice can increase the toxicity of colchicine and should be avoided.
cyclobenzaprine brand name, drug class, MOA
-Flexeril
-Centrally Acting Skeletal Muscle Relaxant
-Cyclobenzaprine relieves skeletal muscle spasm of local origin without interfering with muscle function. It is ineffective in muscle spasm due to CNS disease. Evidence suggests that the net effect of cyclobenzaprine is a reduction in tonic motor activity, influencing both gamma (γ) and alpha (α) motor systems.
cyclobenzaprine indication
-Skeletal muscle spasm
cyclobenzaprine CI
Hypersensitivity to cyclobenzaprine, concomitant MAOI use, heart failure, acute coronary phase of AMI, heart block, arrhythmias, hyperthyroidism
cyclobenzaprine AE
Dizziness, drowsiness, xerostomia
cyclobenzaprine DDI
1. CYP1A2, CYP3A4/5, and CYP2D6 inducers (Increased cyclobenzaprine metabolism reduces cyclobenzaprine effectiveness)
2. CYP1A2, CYP3A4/5, and CYP2D6 inhibitors (Decreased cyclobenzaprine metabolism increases risk of cyclobenzaprine toxicity)
3. CNS depressants (opioids, benzodiazepines, alcohol) (Additive sedative effects)
4. Anticholinergic agents (Enhanced anticholinergic adverse effects)
cyclobenzaprine pt counseling
1. Patients should avoid activities requiring mental alertness or coordination until drug effects are known, as drug may cause dizziness or sedative effects.
2. Take extended-release capsule same time each day.
3. For patients with difficulty swallowing, the extended-release capsules may be opened and granules mixed with applesauce for administration.
diclofenac brand name, drug class, MOA
-Cambia, Voltaren, Zipsor, Zorvolex
-NSAID
-Nonselective inhibitor of cyclo-oxygenase-1 (COX-1) and cyclo-oxygenase-2 (COX-2).
diclofenac indications
-pain
-dysmenorrhea
-migraine
-osteoarthritis
-rheumatoid arthritis
-ankylosing spondylitis
diclofenac BW
Cardiovascular, GI risk, CABG
diclofenac CI
Hypersensitivity to diclofenac, concurrent ketorolac use, asthma, allergic-type reaction following other NSAID use, CABG
diclofenac AE
GI distress, peripheral swelling
diclofenac DDI
1. Aspirin, low-molecular-weight heparins, SSRIs, NSAIDs, pentoxifylline (Additive GI toxicity and increased risk of bleeding)
2. ACEIs, ARBs, beta-blockers, loop and thiazide diuretics (Decreased diuretic and antihypertensive efficacy via decreased renal prostaglandin production)
3. Cholestyramine (Decreased absorption of diclofenac)
4. Most CYP inducers (Increased diclofenac metabolism reduces diclofenac effectiveness)
5. Most CYP inhibitors (Decreased diclofenac metabolism increases risk of diclofenac toxicity)
6. Cyclosporine, tacrolimus (Increased risk of cyclosporine, tacrolimus toxicity, unknown mechanism)
7. Lithium (Decreased renal clearance and increased toxicity of lithium)
8. Methotrexate (Decreased renal clearance and increased toxicity of methotrexate)
9. Pemetrexed (Decreased renal clearance and increased toxicity of pemetrexed)
10. Sulfonylureas (Increased risk of hypoglycemia via inhibition of sulfonylurea metabolism)
11. Warfarin (Both substrates for CYP2C9, competitive metabolism)/
diclofenac pt counseling
1. Take with food or milk to decrease GI upset.
2. Do not chew, split, or crush the delayed-release and extended-release products.
eletriptan brand name, drug class, MOA
-Relpax
-Antimigraine Serotonin Receptor Agonist
-Eletriptan binds with high affinity to serotonin (5-HT) subtypes 1B, 1D, and 1F receptors. It has no significant affinity or pharmacological activity at adrenergic α1, α2, or β; dopaminergic D1 or D2; muscarinic; or opioid receptors. Serotonin receptor agonists are believed to be effective in migraine, either through vasoconstriction (via activation of 5-HT1 receptors located on intracranial blood vessels) or through activation of 5-HT1 receptors on sensory nerve endings in the trigeminal system, resulting in the inhibition of proinflammatory neuropeptide release.
eletriptan indication
-migraine
eletriptan CI
Hypersensitivity to eletriptan, cerebrovascular syndromes, hemiplegic or basilar migraine, ischemic bowel disease, ischemic heart disease, peripheral vascular disease, severe hepatic impairment, uncontrolled HTN, coronary artery vasospasm, cardiac arrythmias 5-HT1 agonist or ergotamine medication
eletriptan AE
Weakness
eletriptan DDI
1. SSRIs (Additive serotonergic effects)
2. CYP3A4/5 inducers (Increased eletriptan metabolism reduces eletriptan effectiveness)
3. CYP3A4/5 inhibitors (Decreased eletriptan metabolism increases risk of eletriptan toxicity)
4. Other 5-HT agonists (Additive pharmacologic effect leading to additive toxicity)
eletriptan pt counseling
1. Should avoid activities requiring mental alertness or coordination until drug effects are realized, as this drug may cause dizziness or somnolence.
2. May take without regard to food.
3. Administer at first sign of migraine.
febuxostat brand name, drug class, MOA
-Uloric
-Xanthine Oxidase Inhibitor
-Selectively inhibits xanthine oxidase, the enzyme responsible for converting xanthine to uric acid. Lowers uric acid and reduces gout.
febuxostat indications
-Hyperuricemia in patients not adequately treated with, or having adverse effects from, allopurinol
febuxostat BW
Increased risk of death (cardiac, all-cause)
febuxostat CI
Concurrent azathioprine or mercaptopurine
febuxostat AE
none known
febuxostat DDI
1. Substrates for xanthine oxidase (azathioprine, didanosine, mercaptopurine, theophylline) (Decreased metabolism of xanthine oxidase substrates and increased toxicity)
2. Pegloticase (Increased risk of infusion reaction and anaphylaxis to pegloticase)
3. Rosuvastatin (Increased concentration and toxicity of rosuvastatin)
4. Ubrogepant (Increased concentration and toxicity of Ubrogepant)
febuxostat pt counseling
1. Take without food.
2. Weight loss and limiting alcohol consumption will reduce gout attacks and should be recommended to all patients.
3. Seek medical attention for severe mood swings, rashes, or abnormal heartbeat.
fentanyl brand name, drug class, MOA
-Duragesic
-Opioid analgesic. C-II
-Fentanyl is a phenylpiperidine opioid agonist with predominant effects on the mu-opioid receptor and is about 50-100 times more potent as an analgesic than morphine.
fentanyl indications
Pain, chronic, including cancer pain
fentanyl BW
Respiratory depression; addiction, CYP3A4/5 interactions, fatalities in children; formulations not interchangeable; care with disposal; REMS program; concurrent use with benzodiazepines or other CNS depressants, neonatal withdrawal, heat exposure with transdermal patch//
fentanyl CI
Acute or postoperative pain, bronchial asthma, hypersensitivity to fentanyl, mild or intermittent pain management, opioid nontolerant patients, paralytic ileus
fentanyl AE
Application site reactions, constipation, GI distress, confusion, headache, urinary retention, fatigue, edema, nausea, vomiting
fentanyl DDI
1. Barbiturates, benzodiazepines, centrally acting muscle relaxants, opioids, phenothiazines (Additive CNS depression)
2. Beta-blockers and calcium channel blockers (Additive hypotension when combined with fentanyl anesthesia)
3. Buprenorphine, opioid mixed agonists/antagonists, opioid antagonists (Precipitation of withdrawal symptoms)
4. CYP3A4/5 inducers (Increased fentanyl metabolism decreases fentanyl efficacy)
5. CYP3A4/5 strong/moderate inhibitors (Decreased fentanyl metabolism increases risk of fentanyl toxicity)
6. MAOIs (Additive respiratory depression)
7. SSRIs, SNRIs, TCAs, Triptans, linezolid (Increased risk of serotonin syndrome)//
fentanyl pt counseling
1. A stimulant laxative should be recommended to prevent constipation.
2. May cause drowsiness; avoid driving or other tasks requiring motor coordination.
3. Avoid alcohol and other CNS depressants.
4. Apply to clean, dry skin.
5. Skin breaks may increase absorption.
6. Remove old patch when new patch applied.
7. Febrile patients may have increased absorption.
8. Patch should be removed prior to MRI scan as it may contain aluminum.
9. Do not cut patch.
hydrocodone brand name, drug class, MOA
-Norco, Lorcet, Vicodin, Hysingla ER
-Opioid Analgesic. C-II
-Hydrocodone binds to opiate receptors, resulting in altered perception of pain.
hydrocodone indications
-pain, severe
hydrocodone BW
Addiction, abuse, misuse, REMS, respiratory depression, accidental ingestion, neonatal opioid withdrawal, alcohol, CYP3A4/5 interactions, hepatotoxicity, concurrent use with benzodiazepines/
hydrocodone CI
Hypersensitivity, paralytic ileus, respiratory depression, severe asthma
hydrocodone AE
Constipation, GI distress, somnolence
hydrocodone DDI
1. Barbiturates, benzodiazepines, centrally acting muscle relaxants, phenothiazines, hydroxyzine (Additive CNS depression)
2. Buprenorphine, opioid mixed agonists/antagonists, opioid antagonists (Precipitation of withdrawal symptoms)
3. CYP3A4/5 inducers (Increased hydrocodone metabolism decreases hydrocodone efficacy)
4. CYP3A4/5 inhibitors (Decreased hydrocodone metabolism and increased hydrocodone toxicity)
5. CYP2D6 inhibitors (Decreased activation of hydrocodone to hydromorphone, decreased hydrocodone efficacy)
6. MAOIs (Additive respiratory depression and increased risk of serotonin syndrome)
7. SSRIs, SNRIs, TCAs, triptans (Increased risk of serotonin syndrome)/
hydrocodone pt counseling
1. Use a stool softener and/or laxative for preventing constipation with chronic use.
2. May cause drowsiness; avoid driving or other tasks requiring motor coordination.
3. Avoid alcohol and other CNS depressants.
hydroxychloroquine brand name, drug class, MOA
-Plaquenil, Sovuna
-Aminoquinoline
-The mechanism of action of hydroxychloroquine is unknown. It is effective in treating P. vivax, P. malariae, and susceptible strains of P. falciparum.
hydroxychloroquine indication
-Lupus erythematosus
-Malaria, suppression
-Malaria, uncomplicated
-Rheumatoid arthritis, maintenance